These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28446570)

  • 1. Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.
    Edwards BD; Greysson-Wong J; Somayaji R; Waddell B; Whelan FJ; Storey DG; Rabin HR; Surette MG; Parkins MD
    J Clin Microbiol; 2017 Jul; 55(7):2074-2085. PubMed ID: 28446570
    [No Abstract]   [Full Text] [Related]  

  • 2. Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.
    Amoureux L; Bador J; Bounoua Zouak F; Chapuis A; de Curraize C; Neuwirth C
    J Cyst Fibros; 2016 Jul; 15(4):486-94. PubMed ID: 26778615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.
    Somayaji R; Stanojevic S; Tullis DE; Stephenson AL; Ratjen F; Waters V
    Ann Am Thorac Soc; 2017 Sep; 14(9):1412-1418. PubMed ID: 28406714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK.
    Coward A; Kenna DT; Perry C; Martin K; Doumith M; Turton JF
    J Cyst Fibros; 2016 Jul; 15(4):479-85. PubMed ID: 26412052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
    Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
    BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.
    Filipic B; Malesevic M; Vasiljevic Z; Lukic J; Novovic K; Kojic M; Jovcic B
    Front Cell Infect Microbiol; 2017; 7():224. PubMed ID: 28611955
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.
    Barrado L; Brañas P; Orellana MÁ; Martínez MT; García G; Otero JR; Chaves F
    J Clin Microbiol; 2013 Jun; 51(6):1927-30. PubMed ID: 23536401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.
    Dupont C; Jumas-Bilak E; Michon AL; Chiron R; Marchandin H
    J Clin Microbiol; 2017 Jan; 55(1):206-215. PubMed ID: 27807149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact.
    Hansen CR; Pressler T; Ridderberg W; Johansen HK; Skov M
    J Cyst Fibros; 2013 Dec; 12(6):609-15. PubMed ID: 23769270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Achromobacter Species in Cystic Fibrosis Patients: Comparison of bla(OXA-114) PCR Amplification, Multilocus Sequence Typing, and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.
    Rodrigues ER; Ferreira AG; Leão RS; Leite CC; Carvalho-Assef AP; Albano RM; Marques EA
    J Clin Microbiol; 2015 Dec; 53(12):3894-6. PubMed ID: 26400790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic characterization of
    Veschetti L; Sandri A; Patuzzo C; Melotti P; Malerba G; Lleo MM
    Microb Genom; 2021 Jul; 7(7):. PubMed ID: 34292148
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study.
    Rønne Hansen C; Pressler T; Høiby N; Gormsen M
    J Cyst Fibros; 2006 Dec; 5(4):245-51. PubMed ID: 16777495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.
    Pereira RH; Leão RS; Carvalho-Assef AP; Albano RM; Rodrigues ER; Firmida MC; Folescu TW; Plotkowski MC; Bernardo VG; Marques EA
    Epidemiol Infect; 2017 Feb; 145(3):600-606. PubMed ID: 27873565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?
    Skolnik K; Nguyen A; Thornton CS; Waddell B; Williamson T; Rabin HR; Parkins MD
    BMC Infect Dis; 2017 Oct; 17(1):660. PubMed ID: 28969684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
    De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
    J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapatient diversity of Achromobacter spp. involved in chronic colonization of Cystic Fibrosis airways.
    Dupont C; Michon AL; Jumas-Bilak E; Nørskov-Lauritsen N; Chiron R; Marchandin H
    Infect Genet Evol; 2015 Jun; 32():214-23. PubMed ID: 25791931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis.
    Recio R; Brañas P; Martínez MT; Chaves F; Orellana MA
    J Med Microbiol; 2018 Jul; 67(7):952-956. PubMed ID: 29787364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans.
    Ridderberg W; Wang M; Nørskov-Lauritsen N
    J Clin Microbiol; 2012 Aug; 50(8):2688-94. PubMed ID: 22675125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and distribution of Achromobacter species in cystic fibrosis.
    Spilker T; Vandamme P; Lipuma JJ
    J Cyst Fibros; 2013 May; 12(3):298-301. PubMed ID: 23141756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis.
    Kerem E; Orenti A; Zolin A; Annicchiarico L; Drevinek P;
    J Cyst Fibros; 2023 Mar; 22(2):334-343. PubMed ID: 36418214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.